Monoclonal antibodies emerge as highly active compounds in the treatment of Multiple Myeloma leading to FDA approval of two molecules just in 2015. In a translational approach, the fully human anti-GRP78 antibody PAT-SM6 was evaluated in vitro and on a first patient who experienced partial remission after treatment with PAT-SM6 in combination with novel agents.
Surface expressed GRP78 suits as target for immunotherapy of Multiple Myeloma, especially when considering late stage or relapse-refractory patients. Furthermore, already approved anti- Multiple Myeloma drugs were identified to positively modulate GRP78 surface expression, and, as a consequence, to act synergistically with PAT-SM6. These results form the basis for upcoming clinical trials evaluating anti-GRP78 immunotherapy particularly in combination with novel agents in larger cohort of patients with Multiple Myeloma.